NCT06855953

Vitamin K and Cognition in Coronary Heart Disease (NutriCog)

Vitamin K Supplementation to Improve Cognition of Patients With Coronary Heart Disease: a Randomized Controlled Pilot Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Montreal Heart Institute · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)

Detailed description

The overall goal of this study is to obtain a preliminary assessment of the effect of a VK1 (phylloquinone) supplementation on cognitive performance (primary outcome) and vascular function (secondary outcome) in adults with stable CHD. Specifically, the investigators will conduct a double-blind, 2-armed, parallel-group intervention study in which 40 men and women aged 60 years and over with stable CHD will be randomly assigned to 0.5 mg phylloquinone per day or matching placebo for a period of 3 months. All participants will have signed a written consent form before taking part in the study

Conditions

• Coronary Heart Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Vitamin K	Participants receive 0.5 mg/day phylloquinone orally for 12 weeks
DIETARY_SUPPLEMENT	Placebo	Participants receive daily placebo for 12 weeks

Timeline

• Start date: 2025-03-17
• Primary completion: 2026-12-01
• Completion: 2027-03-01
• First posted: 2025-03-04
• Last updated: 2025-03-04

Locations

1 site across 1 country: Canada